Abasi Ene-Obong belongs to a generation of African founders trying to change not only who participates in global health, but who builds it. A Nigerian biomedical scientist and entrepreneur, he has become one of the most visible figures in African genomics and biotech, working at the intersection of science, data, and equity.
He is the founder and chief executive officer of Syndicate Bio, a health technology company focused on building more diverse human health datasets and applying AI and machine learning to precision medicine and discovery. Before that, he founded 54gene in 2019, the genomics company that brought the underrepresentation of African populations in global genetic research into sharper public view. Time noted that African populations, despite their genetic diversity, have remained severely underrepresented in global genetic databases.
Ene-Obong trained in genetics, molecular biology, and business. He studied genetics and biotechnology at the University of Calabar, earned a master’s degree in human molecular genetics from Imperial College London, completed a PhD in cancer biology at Barts and The London School of Medicine and Dentistry, and later pursued graduate business training at Keck Graduate Institute.
What makes his profile distinctive is not only the companies he has built, but the question his work keeps pressing into global health: who produces biomedical data, who controls it, and who benefits from the discoveries built on it. That question has become even more urgent as genomics, precision medicine, and AI take on a larger role in the future of healthcare.
His work has earned wide recognition, including inclusion in the Time100 Health 2025 list. More broadly, he represents a new kind of global health actor: scientifically trained, commercially fluent, and focused on building infrastructure rather than simply joining existing systems.
